Genmab A/S Announces Results of Private Placement to Johnson & Johnson Development Corporation

Genmab A/S announced the completion of the private placement of 5,400,000 new shares of DKK 1 nominal value each in Genmab A/S at a subscription price of DKK 88 per new share to Johnson & Johnson Development Corporation, raising gross proceeds to Genmab of DKK 475,200,000. The private placement, which is made in connection with the global license and development agreement for daratumumab (HuMax-CD38) between Genmab and Janssen Biotech, Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson, was originally announced on August 30, 2012. Genmab's current share capital amounts to DKK 50,307,142 after registration of the capital increase with the Danish Business Authority. It is expected that the new shares will be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S on October 17, 2012.